SRP-1001 not checked
Sarepta Therapeutics, Inc. · ARO-DUX4 for Injection
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Single or multiple doses of SRP-1001 by intravenous (IV) infusion”In the company’s words, NCT06131983 on ClinicalTrials.gov
- Tested for
- Muscular Dystrophy, Facioscapulohumeral
- Main trialPhase 1/2
- “The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of SRP-1001 in participants with facioscapulohumeral muscular dystrophy Type 1 (FSHD1). In Part 1 of the study, participants will receive one dose of SRP-1001 or placebo. In Part 2 of the study, participants will receive 4 doses of SRP-1001 or placebo. Participants who complete Part 1 will have the option to re-screen and re-randomize into Part 2. All participants will undergo pre- and post-dose magnetic imaging resonance (MRI)-guided muscle biopsies (a total of 2 biopsies).…”In the company’s words, NCT06131983 on ClinicalTrials.gov
- Other names
- ARO-DUX4 for Injection
Other drugs for Muscular Dystrophy, Facioscapulohumeral
- AOC 1020Avidity Biosciences, Inc. · Phase 3
- EPI-321Epicrispr Biotechnologies, Inc. · Phase 1/2
- ApitegromabScholar Rock · Phase 2
- ForazapadinSatellos Bioscience, Inc. · Phase 2
- SFL-0821Soufflé Therapeutics, Inc. · Phase 1/2
- ULSCRestem, LLC. · Phase 1
Coming up1
- 31 Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Enrolling by invitation | 31 Dec 2028 | Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026